<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574947</url>
  </required_header>
  <id_info>
    <org_study_id>IOLANT</org_study_id>
    <nct_id>NCT04574947</nct_id>
  </id_info>
  <brief_title>Lidocaine And Neuromonitoring in Thyroid Surgery</brief_title>
  <official_title>Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Petersburg State University, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Petersburg State University, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the hypothesis that the quality of recovery with topical&#xD;
      lidocaine is better than placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of neuromonitoring in thyroid surgery imposes a number of special demands for&#xD;
      anaesthetic management. Such demands include avoiding muscle relaxation and local&#xD;
      anaesthesia. Maintaining a balance between the risk of awakening during surgery and&#xD;
      excessively deep anaesthesia in fast track surgery is an important task for the&#xD;
      anaesthesiologist.&#xD;
&#xD;
      Mild anaesthesia in the absence of muscle relaxation increases the risk of developing&#xD;
      laryngeal reflexes, coughing during surgery, while excessively deep anaesthesia slows down&#xD;
      recovery after surgery and increases the risk of arterial hypotension. The frequency and&#xD;
      duration of arterial hypotension, as well as the depth of anesthesia assessed by the&#xD;
      Bispectral index, are independent risk factors for postoperative cardiovascular complications&#xD;
      and long-term mortality. On the other hand, coughing in response to irritation of the&#xD;
      endotracheal tube during recovery from anesthesia is recognized as a risk factor for&#xD;
      respiratory and cardiovascular complications, as well as postoperative wound insufficiency.&#xD;
&#xD;
      Optimization the anesthesia by intravenous infusion of lidocaine can improve anesthesia&#xD;
      controllability, hemodynamic stability and overall anesthesia recovery rates. Local use of&#xD;
      lidocaine, including filling the endotracheal tube cuff with its alkalinized solution, has&#xD;
      also been shown to be effective in reducing the frequency of laryngeal reflexes upon&#xD;
      awakening after surgery of varying duration. However, the efficacy and safety of local use of&#xD;
      lidocaine under neuromonitoring conditions has not been studied. Despite recommendations to&#xD;
      avoid the local use of lidocaine for tracheal intubation, there is evidence of the safety of&#xD;
      this technique in the absence of a negative impact on the quality of neuromonitoring.&#xD;
&#xD;
      The purpose of this study is to test the hypothesis that the quality of recovery with topical&#xD;
      lidocaine is better than placebo. At the same time, the investigators assume that recovery&#xD;
      after surgery will be comparable with both local and intravenous use. Intergroup differences&#xD;
      in arterial hypotension, depth of anesthesia and intraoperative neuromonitoring parameters&#xD;
      will also be investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of recovery 40 questionnaire</measure>
    <time_frame>First postoperative day</time_frame>
    <description>Minimum and maximum values: 40 and 200, where higher scores mean a better outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypotension incidence</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Incidence of arterial hypotension (SBP &lt;60 mm Hg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension duration</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Cumulative duration of arterial hypotension (SBP &lt;60 mm Hg) expressed in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough rate</measure>
    <time_frame>In the operating room and during awakening.</time_frame>
    <description>Frequency of laryngeal reflexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal bispectral index</measure>
    <time_frame>During surgery</time_frame>
    <description>Minimal observed intraoperative bispectral index value. Values less than 40 mean a worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index less then 40</measure>
    <time_frame>During surgery</time_frame>
    <description>Cumulative duration of bispectral index less than 40. Values less than 40 mean a worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amplitude</measure>
    <time_frame>During surgery</time_frame>
    <description>Amplitude of electromyographic potential during neuromonitoring of recurrent nerve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency</measure>
    <time_frame>During surgery</time_frame>
    <description>Latency of electromyographic potential during neuromonitoring of recurrent nerve</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">231</enrollment>
  <condition>Thyroid Neoplasm</condition>
  <condition>Parathyroid Neoplasms</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Intravenous lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous lidocaine</intervention_name>
    <description>Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.</description>
    <arm_group_label>Intravenous lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous placebo</intervention_name>
    <description>During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Topical lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-cuff lidocaine</intervention_name>
    <description>The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.</description>
    <arm_group_label>Topical lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-cuff placebo</intervention_name>
    <description>The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.</description>
    <arm_group_label>Intravenous lidocaine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Planned thyroid surgery&#xD;
&#xD;
          -  Age&gt; 45 years&#xD;
&#xD;
          -  Signed informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Redo surgery&#xD;
&#xD;
          -  Contraindications for lidocaine use&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Enrolment to another randomised clinical trial within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sergey Efremov</last_name>
    <phone>79137946090</phone>
    <email>sergefremov@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexey Kulikov</last_name>
    <phone>79217896909</phone>
    <email>alexeykulikov1987@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Petersburg State University Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efremov Sergey, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexey Kulikov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Zolotuho</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Viktor Makarin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilya Sleptsov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleg Kuleshov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roman Chernikov, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandr Khomenko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Petersburg State University, Russia</investigator_affiliation>
    <investigator_full_name>Efremov Sergey</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

